ADMA Biologics Inc

Stocks with insider trader activity include PROV, ADMA and VR

Stocks with insider trader activity include L, ADMA and CSC

Stocks with insider trader activity include TACT, ADMA and CBPX

Stocks with insider trader activity include CSGS, KCG and ADMA

Market action has been mixed but there are some signs of rotation out of the Magnificent Seven.

* But I'm checking it twice and waiting to buy until the Fed speaks on Wednesday.

Here's what is making me more cautious and how I plan to navigate the environment.

Upcoming quaterly results from these names should result in significant movement on the news.

As earnings season begins to pick up steam, here's the latest on my positions and what I expect next.

This biologics name has been a big winner and a recent setback won't stand in the way.

As we await the Fed's rate decision and press conference, here are the nearly two-dozen names on my radar.

Here are the stocks I'm watching and hunting right now, as we see a suspicious bounce on Monday.

All these names have what I consider to be strong fundamentals. The main issue is finding good entries.

Let's recap winning trades from Helene Meisler, Doug Kass, Bret Jensen, and James "Rev Shark" DePorre. C, DIS, EXEL, ADMA, and AAPL.

I've been using the weakness to my advantage in select areas, but there are key things to understand about wading into this kind of market.

As Magnificent Seven names lose their mojo, I am looking at a flurry of little stocks and an investment with major outsized potential.

Conventional wisdom is that we should buy low and sell high, but sometimes, the better trade is to buy high and sell even higher.

Time for an update on ADMA Biologics.

Outside of Apple, which is regaining some of its luster, markets are a mess Tuesday.

As I look for new ideas, here are updates on some of my current small-cap positions.

Let's circle back on some of my recent covered call trades and how I'm playing them now.

The latest celebration may be already losing traction, but here's why it's been beneficial overall.

This is an excellent time to review positions and consider upcoming strategies. These stocks are among those on my radar right now.

The world-renowned hedge fund manager explains what could happen to the S&P 500 in 2025.

Credit card holders should keep an eye out for this update.

Doug McMillon is putting himself in front of a potential issue in 2025.